

**LIMITED TARIFF BENEFIT DISCLOSURE STATEMENT**

Provide a signed hard copy to the Clerk of the Senate Committee on Finance located at 219 Dirksen SOB and a PDF version sent via email to [mtb2009@finance-dem.senate.gov](mailto:mtb2009@finance-dem.senate.gov) not later than five business days after the date of introduction of the bill.

*Please be aware that this form will be made available to the public, media, and any other interested parties.*

**Part I.** This form is being submitted for S. 2067, which I introduced in the Senate on October 29, 2009. If the bill referenced above is a modification of a previously introduced bill to reflect technical changes, please indicate the previous bill number here: S. \_\_\_\_\_.

**Part II.** Please indicate the type of disclosure below: (Please check one only)

- ☒ The bill referenced in Part I is reasonably anticipated to benefit 10 or fewer individuals or entities, and as such constitutes a Limited Tariff Benefit. (Complete Part III)
- ☐ The bill referenced in Part I is reasonably anticipated to benefit more than 10 individuals or entities, and as such does not constitute a Limited Tariff Benefit.

**Part III.** Provide the information below in subparts A, B, and C if the bill referenced above is a Limited Tariff Benefit.

**A. Anticipated Beneficiaries:**

Nichino America, Inc.

_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

**B. Purpose of the Limited Tariff Benefit:**

This bill would temporarily suspend the general rate of duty on:

(Z)-2-tert-butylimino-3-isopropyl-5-phenyl-1,3,5-thiadiazinan-4-one (Bupropion)  
(CAS No. 69327-76-0) (provided for in subheading 2934.99.16)

**C. Financial Benefit Certification**

☒ I hereby certify that neither I nor my immediate family has a financial interest in the above described limited tariff benefit.

Thomas R. Carpenter  
(Member Signature)

11-03-2009  
Date

Senator Thomas Carper

---

(Print Member name)